In a prespecified secondary analysis of the STEP-HFpEF trial, semagludtide treatment was associated with improvements in KCCQ-CSS and body weight, as well as trial secondary endpoints, across the spectrum of obesity classes, with the magnitude of beneficial effects being proportional to the extent of weight loss.
- Barry A. Borlaug
- Dalane W. Kitzman
- Mikhail N. Kosiborod
